Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 3, 2026 · Leadership change · Investor press release · Financial statements
Celularity Inc
9
Leadership change
Jun 3, 2026
| Item 5.02 | Director or executive officer departure or appointment |
| Item 7.01 | Regulation FD disclosure (investor press release or presentation) |
| Item 9.01 | Financial statements and exhibits |
Celularity Inc filed this to disclose a change in directors or executive officers: appointments, departures, or role changes that can signal a strategic shift.
1 Celularity Appoints Rick Gonzalez as Chief Commercial Officer ● Appointment supports Celularity’s focus on longevity, regenerative medicine and preservation of human performance by advancing commercialization of cenplacel-L and Lifebank FLORHAM PARK, NJ, June 3, 2026 (GLOBE NEWSWIRE), Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular and regenerative therapies, today ann…
This filing reports Item 5.02 (director or executive officer departure or appointment). These item codes often precede or accompany restructuring, leadership changes, or deals that can shift headcount.
Celularity Inc reported material events that can affect workforce planning. cutoffs surfaces the filing alongside WARN layoffs, H-1B activity, and company signals.
